EKE. S. Kolobanova

E. S. Kolobanova

*This is an algorithmically generated author record based on publicly available information.

E. S. Kolobanova has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Retrospective analysis of BUCEN score prognostic value in Russian population of patients with advanced adrenocortical carcinoma treated with platinum-based chemotherapy in combination with mitotane

    by Ya. A. Zhulikov, E. V. Artamonova, A. Yu. Kolycheva, E. I. Kovalenko, V. Yu. Bokhyan, E. V. Evdokimova, E. S. Kolobanova, O. A. Martynova, D. V. Rogozhin, V. A. Gorbunova, et al.

    Introduction. Currently, the algorithm for selecting first-line treatment for advanced adrenocortical carcinoma (ACC) is not clearly defined; the choice between mitotane monotherapy and its combination with platinum-based chemotherapy remains controversial. In a large retrospective study (n = 439), the BUCEN scoring system was proposed as a predictor of treatment response, which could help determine first-line therapy [9]. Our study aimed to evaluate the prognostic value of the BUCEN scores in the Russian population of patients with advanced ACC, treated with a combination of platinum-based chemotherapy and mitotane. Materials and Methods. This retrospective single-center study included patients aged ≥ 18 years with advanced ACC and pre-assessed BUCEN scores who received platinum-based chemotherapy in combination with mitotane at the N. N. Blokhin National Medical Research Center of Oncology between 2016 and 2025. Result. The study included 63 patients with BUCEN scores of 0–2 (n = 31; 49.2 %) and ≥ 3 (n = 32; 50.8 %). Fifty patients (79.4 %) received etoposide + cisplatin + doxorubicin (EDP), 5 patients (7.9 %) received etoposide + cisplatin (EP), and 8 (12.7 %) received etoposide + carboplatin (EC). Therapeutic serum levels of mitotane were achieved in 42 patients (66.7 %). The objective response rate (ORR), disease control rate (DCR) at ≥ 6 months, and DCR at ≥ 12 months were 20.6 %, 62.3 %, and 26.3 %, respectively. A BUCEN score of 0–2 was associated with an improved ORR (p = 0.03), a DCR at ≥ 6 months (p < 0.01), and a DCR at ≥ 12 months (p = 0.03). A multivariate analysis revealed that non-anthracycline regimens in patients with BUCEN ≥ 3 were associated with a statistically significant decrease in progression-free survival (PFS) and overall survival (OS). A statistically significant OS improvement was observed in patients with recurrence-free survival of ≥ 12 months post-adrenalectomy (p = 0.04). Conclusion. The BUCEN scoring system is reproducible, simple to use, and could be applied for the stratification of patients with advanced ACC. Implementation of this system in clinical practice to pre-select patients for mitotane monotherapy as a first-line treatment requires prospective validation. The significantly poorer outcomes in the EP / EC group may partly reflect patient characteristics, as these regimens were used in those with contraindications to anthracyclines or cisplatin. However, based on our data, we do not recommend non-anthracycline regimens in patients without contraindications to EDP chemotherapy.

  • On the Topic of Gossypibomas: 3 Clinical Cases

    by A. B. Lukianchenko, M. P. Nikulin, E. S. Kolobanova, K. A. Romanova, E. B. Kodzoeva

    Gossypiboma (a retained surgical textile) poses significant challenges for preoperative diagnosis as it frequently mimics a tumor. This article presents three clinical cases of female patients in whom mass lesions were detected in the abdominal cavity and pelvis after previous laparotomies. These lesions were initially interpreted as neoplastic lesions. In all cases, the diagnosis of gossypiboma was established only intraoperatively and confirmed histologically. These cases underscore the critical importance of obtaining a thorough surgical history and recognizing characteristic imaging features to include gossypiboma in the differential diagnosis and prevent diagnostic errors.

  • Open Access

    Prospective, Single-Center, Phase II Study to Standardize the Mitotane Dosing Regimen in Combination with Platinum-Based Chemotherapy in the First-Line Treatment for Adrenocortical Cancer

    by Ярослав Андреевич Жуликов, Елена Владимировна Артамонова, Елена Игоревна Коваленко, Ваган Юрикович Бохян, Анна Александровна Рослякова, Екатерина Вадимовна Евдокимова, Кизлер Рифкатовна Гаджиева, Ольга Андреевна Мартынова, Евгения Сергеевна Колобанова, Иван Сократович Стилиди

    Введение. Комбинация химиотерапии EDP (этопозида, доксорубицина, цисплатина) с митотаном является стандартом первой линии терапии адренокортикального рака (АКР). Достижение терапевтических концентраций митотана связано с улучшением выживаемости без прогрессирования (ВБП) и общей выживаемости (ОВ) в ряде исследований. В большинстве опубликованных работ схема назначения митотана определялась локальными протоколами, что подчеркивает необходимость валидации протокола по его назначению и создания унифицированного режима дозирования. Материалы и методы. Проведено одноцентровое проспективное исследование II фазы с использованием двухэтапного дизайна Симона. В исследование включали пациентов с местнораспространенным или метастатическим АКР, ECOG 0–1, ранее не получавших митотан. Первичная конечная точка — частота достижения терапевтической концентрации митотана (14–20 мкг/мл). Статистическая гипотеза предполагала увеличение частоты достижения терапевтической концентрации с 50 до 70 % (β = 0,2; α = 0,05). Вторичные конечные точки — частота объективного ответа и контроля болезни ≥ 6 мес, ВБП, ОВ, безопасность терапии. Митотан назначался в начальной дозе 2 г/сут с постепенной эскалацией каждые 3-5 дней на 0,5 г до 4 г/сут, с последующей коррекцией дозы в зависимости от его концентрации в крови. Все пациенты одновременно с митотаном получали стандартную платиносодержащую химиотерапию (EDP или EP/EC). Результаты. В исследование включено 47 пациентов: 27 мужчин (57,4 %) и 20 женщин (42,5 %). Все пациенты получали платиносодержащую химиотерапию — 45 (95,8 %) EDP, 2 — EP/EC. При медиане наблюдения 12,4 мес терапевтическая концентрация митотана достигнута в 72,3 % (n = 34) случаев, медиана времени до ее достижения — 4,3 мес (95 % ДИ 3,3–5,3 мес). Частота объективного ответа составила 29,7 % (n = 14), контроль заболевания ≥ 6 мес — 63,8 % (n = 30). Медиана ВБП — 8,4 мес (95 % ДИ 4,2–12,6), медиана ОВ — 24,6 мес (9,9–44,6). Профиль нежелательных явлений не отличался от ранее описанного. Выводы. Разработанный режим митотана обеспечивает быстрое и безопасное достижение терапевтической концентрации у большинства пациентов и может быть рекомендован для рутинной практики.


  • Tumor of the Renal Pelvis Accompanying Coral Nephrolithiasis

    by I. S. Grashchenko, N. Ts. Drobot, A. V. Klimov, O. A. Halmurzaev, S. D. Bejanova, B. M. Medvedeva, K. A. Romanova, E. S. Kolobanova, M. G. Lapteva, A. B. Lukianchenko

    Cancer of the renal pelvis, in particular the squamous cell form, is an extremely rare neoplasm of this localization. Chronic inflammation is thought to be a risk factor for this disease due to the presence of stones in the collecting system. Having no specific clinical manifestations, this tumor is often an incidental finding identified during examination of patients for other reasons.This article presents a clinical case of squamous cell carcinoma of the renal pelvis in a patient with a long course of urolithiasis and the presence of staghorn stones, complicated by a kidney abscess diagnosed by CT and MRI.


  • Open Access

    Rare Manifestation of Neuroendocrine Pancreatic Tumor: Difficulties of Diagnosis

    by A. M. Belozerskikh, E. S. Kolobanova, A. B. Lukianchenko, N. C. Drobot, K. A. Romanova, B. M. Medvedeva

    A rare case of neuroendocrine pancreatic tumor is presented. The clinical, CT/MRI and morphological manifestations of the tumor are described. Some differential diagnosis’ problems among a spectrum of pancreatic tumor and tumor-like cystic lesions are being discussed.


  • Open Access

    Possibilities of Diffusion-Weighted MRI in Clarification of the Degree of Malignance of Recurrent Retroperitoneal Liposarcomas

    by E. S. Kolobanova, B. M. Medvedeva, M. G. Lapteva

    Возможности диффузионно-взвешенной МРТ в уточнении степени злокачественности рецидивных забрюшинных липосарком

  • Open Access

    Possibilities of Diffusion-Weighted MRI in the Differential Diagnosis of Early Recurrences of Retroperitoneal Liposarcomas and Postoperative Changes

    by E. S. Kolobanova, B. M. Medvedeva

    Purpose: To evaluate contrast-enhanced magnetic resonance imaging (CE‑MRI) and diffusion-weighted (DWI) in the detection and differential diagnosis of recurrent of retroperitoneal liposarcomas with postoperative changes.Material and methods: The retrospective study included of 23 patients previously operated on for retroperitoneal inorganic liposarcomas. All patients underwent MRI of the abdominal cavity and pelvis with intravenous contrast with further assessment of the size, shape, structure and characteristics of the accumulation of contrast agent in the detected formation.Results: Morphological verification were performed in 17 patients (74 %), in 6 cases (26 %) patients were left for dynamic control for 1–3 years. Local relapses were detected in 16 patients (67 %), postoperative changes — in 7 (33 %) patients, of which in 2 cases deformation of adipose tissue and fibrotic changes in the area of surgery was determined, in 3 patients granulomas were revealed, and in two patients — volvulus of the greater omentum and lymphocele. The sensitivity of MRI with intravenous contrast enhancement was 68.7 %, specificity 71.4 % and accuracy 69.6 %. The addition of DWI to the standard MRI protocol in patients with suspected recurrence of retroperitoneal liposarcoma to increase the sensitivity of the method in the differential diagnosis of recurrent drugs from postoperative changes to 93.7 % (15 out of 16), specificity up to 100 % (7 out of 7) and accuracy up to 95.6 % (22 out of 23).Conclusion: The joint use of MRI with intravenous contrast and DW‑MRI increases the information content in the detection and differential diagnosis of small-sized recurrent tumors in dedifferentiated and myxoid types of liposarcomas with postoperative changes.


  • Open Access

    Problems in the differential diagnosis of abdominal non-organ tumors

    by E. S. Kolobanova, B. M. Medvedeva

    Rationale: The differential diagnosis between lesions requiring surgical intervention and those necessitating medical treatment poses a significant problem for current imaging methods of fat-containing masses in the small intestine mesenterium.Aim: To identify differential diagnostic criteria for various fat-containing neoplasms of abdominal cavity at the preoperative stage.Materials and methods: This retrospective study included data from 29 patients (16 women and 13 men, aged 32 to 81 years, mean age 56 years) with fat-containing masses in the small intestine mesenterium who had undergone preoperative examination at N.N. Blokhin National Medical Research Center of Oncology from 2016 to 2020. Abdominal computed tomography (CT) with intravenous contrast enhancement and assessment of the size, contours, structure and involvement of main vessels was performed in all patients. To interpret single soft tissue nodes within the mass, we used our own list of main CT symptoms (number, size, shape, contours and structure of nodes, degree of their contrast enhancement, and maximal amplification).Results: Fat-containing abdominal masses were morphologically verified as follows: mesenteric panniculitis 13 (45%), well differentiated liposarcoma 10 (35%), lymphoproliferative disorders 4 (14%), lipoma and Castleman disease 1 case each (3%). Twelve (12) of 29 patients (41%) had surgery for various types of tumors, while 17 (59%) patients received appropriate medical treatment after a puncture biopsy-based morphological diagnosis. The CT sensitivity for the detection of fat-containing abdominal neoplasms in our series was 93,1%. The paper describes the radiological signs of the above mentioned mass types with an emphasis on the complexity of their diagnosis.Conclusion: In most cases, CT data can accurately differentiate abdominal liposarcomas from other benign and malignant masses in the small intestine mesenterium.


  • The Potentials and Role of Diffusion-Weighted Magnetic Resonance Imaging in Evaluating the Efficiency of Antitumor Treatment of Patients with Breast Liver Metastasis

    by А. B. Lukiyanchenko, B. М. Medvedeva, E. S. Kolobanova, К. A. Romanova, S. S. Magamedova

    Objective.To compare the informative value of using dynamic magnetic resonance imaging (MRI) and diffusion-weighted MRI (DW-MRI) in patients with breast liver metastasis during chemotherapy.Material and methods.The investigation enrolled 30 patients with breast liver metastasis during their treatment. The results of standard intravenous contrast-enhanced abdominal MRI studies (by evaluating the liver in the arterial, venous, and delayed phases) were compared with those of DW-MRI with different B-factor values (50, 400 and 800 sec/mm2).Results.Comparison of the findings of initial studies prior to chemotherapy (those of only dynamic intravenous contrast-enhanced MRI and only DW-MRI) revealed a complete correspondence with the number of detected foci in 10 patients. Ten patients had a larger number of metastatic foci at DW-MRI than at intravenous contrast-enhanced MRI, in the aggregate by 44 foci more (of them 36 foci measured less than 1 cm). The remaining 10 of the 30 patients were found to have multiple, unquantifiable (more than 20–40) metastatic foci of various sizes (1–6 cm) at both intravenous contrast-enhanced MRI and DW-MRI. Nineteen of the 30 patients were followed up during their chemotherapy. Seven of the 19 patients showed a stabilized liver metastatic process that was similarly evidenced by both techniques. Eleven of the 19 patients were observed to have a progressive metastatic process that was reflected by the similar increase in the number and size of metastases in 5 of the 11 patients, as shown by both of the above techniques. In the remaining 6 of the 11 patients, the number of newly detected liver tumors proved to be larger at DW-MRI than at intravenous contrast-enhanced MRI. Both techniques showed that the last patient of the 19 cases had a decrease in the number of small liver metastases that maintained their sizes (less than 1 cm).Conclusion.DW-MRI has been shown to be much more effective in detecting metastases than conventional intravenous contrast-enhanced MRI, which necessitates the inclusion of this technique in standard abdominal MRI protocols for patients with liver metastasis.


  • Open Access

    PARADUODENAL PANCREATITIS (GROOVE PANCREATITIS)

    by A. B. Luk’yAnchenko, K. A. Romanova, B. M. Medvedeva, E. S. Kolobanova

    ПАРАДУОДЕНАЛЬНЫЙ ПАНКРЕАТИТ (GROOVE PANCREATITIS)